An embedded gene choice methodology utilizing knockoffs optimizing neural community
Background: Gene alternative refers to find a small subset of discriminant genes from the gene expression profiles. The way in which to decide on genes that affect specific phenotypic traits efficiently is an important evaluation work throughout the topic of biology. The neural group has greater changing into functionality when dealing with nonlinear info, and it’ll in all probability seize choices robotically and flexibly. On this work, we advise an embedded gene alternative methodology using neural group.
The important genes could also be obtained by calculating the burden coefficient after the teaching is completed. In an effort to treatment the difficulty of black area of neural group and extra make the teaching outcomes interpretable in neural group, we use the idea of knockoffs to assemble the knockoff attribute genes of the distinctive attribute genes. This system not solely make each attribute gene to compete with each other, however moreover make each attribute gene compete with its knockoff attribute gene. This methodology could assist to select the essential factor genes that affect the decision-making of neural networks.
Outcomes: We use maize carotenoids, tocopherol methyltransferase, raffinose family oligosaccharides and human breast most cancers dataset to do verification and analysis.
Conclusions: The experiment outcomes show that the knockoffs optimizing neural group methodology has greater detection impression than the other current algorithms, and particularly for processing the nonlinear gene expression and phenotype info.
geno-type
 Fenretinide |
|
HY-15373 |
MedChemExpress |
10mM/1mL |
EUR 127.71 |
|
Description: Fenretinide (4-HPR) is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death. |
Fenretinide |
|
MBS384058-5x100mg |
MyBiosource |
5x100mg |
EUR 990 |
 Fenretinide-d4 |
|
HY-110360 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: Fenretinide-d4 is the deuterium labeled Fenretinide. |
) Fenretinide (4-HPR) |
|
abx282632-100g |
Abbexa |
100 µg |
Ask for price |
Fenretinide (4-HPR) |
|
abx282632-20g |
Abbexa |
20 µg |
EUR 143.75 |
Fenretinide (4-HPR) |
|
abx282632-50g |
Abbexa |
50 µg |
EUR 362.5 |
 Fenretinide glucuronide-d4 |
|
HY-143957S |
MedChemExpress |
1mg |
Ask for price |
|
Description: Fenretinide glucuronide-d4 is the deuterium labeled Fenretinide glucuronide[1]. |
 4'-Hydroxy Fenretinide-d4 |
|
HY-143958S |
MedChemExpress |
1mg |
Ask for price |
|
Description: 4'-Hydroxy Fenretinide-d4 is the deuterium labeled 4'-Hydroxy Fenretinide[1]. |
retinamide)) Fenretinide (N-(4-Hydroxyphenyl)retinamide) |
|
MBS6081236-10mg |
MyBiosource |
10(mg |
EUR 500 |
Fenretinide (N-(4-Hydroxyphenyl)retinamide) |
|
MBS6081236-5x10mg |
MyBiosource |
5x10mg |
EUR 2090 |
 FEN1, 1-380aa, Human, E Coli |
|
MBS203445-002mg |
MyBiosource |
0.02mg |
EUR 230 |
FEN1, 1-380aa, Human, E Coli |
|
MBS203445-01mg |
MyBiosource |
0.1mg |
EUR 405 |
FEN1, 1-380aa, Human, E Coli |
|
MBS203445-05mg |
MyBiosource |
0.5mg |
EUR 985 |
FEN1, 1-380aa, Human, E Coli |
|
MBS203445-5x05mg |
MyBiosource |
5x0.5mg |
EUR 4180 |
 Human Recombinant Protein) FEN1 (NM_004111) Human Recombinant Protein |
|
E45H41222M5 |
EnoGene |
20 ug |
EUR 785.42 |
 Mouse Recombinant Protein) Fen1 (NM_007999) Mouse Recombinant Protein |
|
E45M43496M5 |
EnoGene |
20 ug |
EUR 1924.54 |
 Human Over-expression Lysate) FEN1 (NM_004111) Human Over-expression Lysate |
|
E45H19061-2 |
EnoGene |
20 ug |
EUR 395 |
FEN1 (NM_004111) Human Over-expression Lysate |
|
LS002237 |
BosterBio |
100ug |
EUR 628 |
|
|
|
Description: Transient overexpression lysate of flap structure-specific endonuclease 1 (FEN1) |
 FEN1 |
|
CSB-CL008585HU |
Cusabio |
10 μg plasmid + 200μl Glycerol |
Ask for price |
FEN1 |
|
enz-468 |
ProSpec Tany |
5µg |
EUR 60 |
|
Description: Recombinant Human Flap Structure-Specific Endonuclease 1 |
FEN1 |
|
MBS8561543-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
FEN1 |
|
MBS8561543-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
FEN1 |
|
MBS8561543-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
FEN1 |
|
MBS8561543-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
 - Mouse flap structure specific endonuclease 1 (Fen1), 200ul, >10^7 TU/mL) Lenti ORF particles, Fen1 (GFP-tagged) - Mouse flap structure specific endonuclease 1 (Fen1), 200ul, >10^7 TU/mL |
|
MR220960L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
 - Rat flap structure-specific endonuclease 1 (Fen1), 200ul, >10^7 TU/mL) Lenti ORF particles, Fen1 (GFP-tagged ORF) - Rat flap structure-specific endonuclease 1 (Fen1), 200ul, >10^7 TU/mL |
|
RR207787L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
 - Mouse flap structure specific endonuclease 1 (Fen1), 200ul, >10^7 TU/mL) Lenti ORF particles, Fen1 (Myc-DDK-tagged) - Mouse flap structure specific endonuclease 1 (Fen1), 200ul, >10^7 TU/mL |
|
MR220960L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
 - Human flap structure-specific endonuclease 1 (FEN1), 200ul, >10^7 TU/mL) Lenti ORF particles, FEN1 (Myc-DDK tagged) - Human flap structure-specific endonuclease 1 (FEN1), 200ul, >10^7 TU/mL |
|
RC201785L1V |
Origene Technologies GmbH |
200 µl |
Ask for price |
 - Human flap structure-specific endonuclease 1 (FEN1), 200ul, >10^7 TU/mL) Lenti ORF particles, FEN1 (mGFP-tagged) - Human flap structure-specific endonuclease 1 (FEN1), 200ul, >10^7 TU/mL |
|
RC201785L2V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, FEN1 (Myc-DDK tagged) - Human flap structure-specific endonuclease 1 (FEN1), 200ul, >10^7 TU/mL |
|
RC201785L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, FEN1 (mGFP-tagged) - Human flap structure-specific endonuclease 1 (FEN1), 200ul, >10^7 TU/mL |
|
RC201785L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
 FEN1-IN-5 |
|
HY-153790 |
MedChemExpress |
10 mg |
EUR 308.45 |
|
Description: FEN1-IN-5 (compound 12A) is a potent inhibitor of Flap endonuclease-1 (FEN1, IC50=12 nM), involving in DNA repair[1]. |
 FEN1-IN-6 |
|
HY-153791 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: FEN1-IN-6 (compound 9) is a potent inhibitor of Flap endonuclease-1 (FEN1, IC50=10 nM), involving in mammalian cells to repair DNA damage. FEN1-IN-6 also targets to related endonuclease, xeroderma pigmentosum G (XPG) with an IC50 value of 23 nM[1]. |
 FEN1-IN-7 |
|
HY-153792 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: FEN1-IN-7 (compound 16) is a selective inhibitor of Flap endonuclease-1 (FEN1, IC50=18 nM), involving in mammalian cells to repair DNA damage. FEN1-IN-7 also targets to related endonuclease, xeroderma pigmentosum G (XPG) with an IC50 value of 3.04 μM. FEN1-IN-7 increases the cellular sensitivity of cancer cells to potent DNA alkylating agents or methylating agents[1]. |
 FEN1-IN-1 |
|
MBS133109-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 FEN1-IN-3 |
|
HY-136484 |
MedChemExpress |
10 mg |
EUR 487.02 |
|
Description: FEN1-IN-3 (Compound 4) is a human flap endonuclease-1 (hFEN1) inhibitor. FEN1-IN-3 stabilizes hFEN1 with an EC50 of 6.8 μM[1]. |
 FEN1-IN-4 |
|
HY-136485 |
MedChemExpress |
1 mg |
EUR 535.72 |
|
Description: FEN1-IN-4 (Compound 2) is a human flap endonuclease-1 (hFEN1) inhibitor[1]. |
 FEN1-IN-2 |
|
HY-122695 |
MedChemExpress |
10 mg |
EUR 1028.15 |
|
Description: FEN1-IN-2 (compound 20) is a flap endonuclease 1 (FEN1) inhibitor, with IC50 values of 3 nM and 226 nM for FEN1 and XPG, respectively[1]. |
FEN1-IN-1 |
|
HY-123834 |
MedChemExpress |
1 mg |
EUR 205.63 |
|
Description: FEN1-IN-1 (compound 1) is a flap endonuclease 1 (FEN1) inhibitor. FEN1-IN-1 binds to the active site of FEN1 and partly achieves inhibition by the co-ordination of Mg2+ ions[1]. |
 - Rat flap structure-specific endonuclease 1 (Fen1), (10 ug)) Fen1 (untagged ORF) - Rat flap structure-specific endonuclease 1 (Fen1), (10 ug) |
|
RN207787 |
Origene Technologies GmbH |
10 µg |
Ask for price |
 - Rat flap structure-specific endonuclease 1 (Fen1), 200ul, >10^7 TU/mL) Lenti ORF particles, Fen1 (Myc-DDK-tagged ORF) - Rat flap structure-specific endonuclease 1 (Fen1), 200ul, >10^7 TU/mL |
|
RR207787L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
 - Mouse flap structure specific endonuclease 1 (Fen1), (10ug)) Fen1 (GFP-tagged) - Mouse flap structure specific endonuclease 1 (Fen1), (10ug) |
|
MG220960 |
Origene Technologies GmbH |
10 µg |
Ask for price |
 - Mouse flap structure specific endonuclease 1 (Fen1), (10ug)) Fen1 (untagged) - Mouse flap structure specific endonuclease 1 (Fen1), (10ug) |
|
MC208478 |
Origene Technologies GmbH |
10 µg |
Ask for price |
 - Human flap structure-specific endonuclease 1 (FEN1)) FEN1 (GFP-tagged) - Human flap structure-specific endonuclease 1 (FEN1) |
|
RG201785 |
Origene Technologies GmbH |
10 µg |
Ask for price |
 Rat FEN1 siRNA |
|
20-abx916746 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
) FEN1 siRNA (Rat) |
|
MBS8223612-15nmol |
MyBiosource |
15nmol |
EUR 405 |
FEN1 siRNA (Rat) |
|
MBS8223612-30nmol |
MyBiosource |
30nmol |
EUR 565 |
FEN1 siRNA (Rat) |
|
MBS8223612-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
 FEN-1 mouse mAb |
|
UB-GEN-1074 |
UpingBio |
100 ul |
EUR 200 |
FEN-1 mouse mAb |
|
UB-GEN-1075 |
UpingBio |
100 ul |
EUR 200 |
 - Mouse flap structure specific endonuclease 1 (Fen1)) Fen1 (Myc-DDK-tagged) - Mouse flap structure specific endonuclease 1 (Fen1) |
|
MR220960 |
Origene Technologies GmbH |
10 µg |
Ask for price |
 - Rat flap structure-specific endonuclease 1 (Fen1), (10 ug)) Fen1 (Myc-DDK-tagged ORF) - Rat flap structure-specific endonuclease 1 (Fen1), (10 ug) |
|
RR207787 |
Origene Technologies GmbH |
10 µg |
Ask for price |
 FEN-1 Rabbit mAb |
|
A8999 |
Abclonal |
20 μL |
EUR 1657.89 |
|
|
|
Description: A synthetic peptide corresponding to a sequence within amino acids 5000-5100 of human MUC2 (Q02817). |
 FEN1 Rabbit mAb |
|
52758 |
SAB |
100ul |
EUR 499 |
FEN1 Rabbit mAb |
|
59492 |
SAB |
100ul |
EUR 339 |
 FEN1 protein |
|
30R-1442 |
Fitzgerald |
100 ug |
EUR 410 |
|
|
|
Description: Purified recombinant Human FEN1 protein |
 FEN-1 Rabbit pAb |
|
A0129 |
Abclonal |
200μL |
EUR 173.58 |
 FEN1 Rabbit pAb |
|
A0129-100ul |
Abclonal |
100 ul |
EUR 369.6 |
FEN1 Rabbit pAb |
|
A0129-200ul |
Abclonal |
200 ul |
EUR 550.8 |
FEN1 Rabbit pAb |
|
A0129-20ul |
Abclonal |
20 ul |
Ask for price |
FEN1 Rabbit pAb |
|
A0129-50ul |
Abclonal |
50 ul |
Ask for price |
FEN-1 Rabbit pAb |
|
A1175 |
Abclonal |
200μL |
EUR 173.58 |
FEN1 Rabbit pAb |
|
A1175-200ul |
Abclonal |
200 ul |
EUR 550.8 |
FEN1 Rabbit pAb |
|
A1175-20ul |
Abclonal |
20 ul |
EUR 219.6 |
 FEN1 cDNA Clone |
|
MBS1271477-001mgPlasmid02mLGlycerolStock |
MyBiosource |
0.01mgPlasmid+0.2mLGlycerol-Stock |
EUR 200 |
FEN1 cDNA Clone |
|
MBS1271477-5x001mgPlasmid5x02mLGlycerolStock |
MyBiosource |
5x0.01mgPlasmid+5x0.2mLGlycerol-Stock |
EUR 855 |
FEN-1 Rabbit mAb |
|
E45R12158N |
EnoGene |
50 ul |
EUR 346.5 |
FEN1 Rabbit pAb |
|
E2381904 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
FEN1 Rabbit mAb |
|
E2R26747 |
EnoGene |
100ul |
EUR 255 |
|
Description: Available in various conjugation types. |
FEN1 Rabbit mAb |
|
E2R381904 |
EnoGene |
100ul |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
FEN-1 Rabbit pAb |
|
E45R18628N |
EnoGene |
50 ul |
EUR 297.75 |
FEN1 Rabbit pAb |
|
E2501175 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
 FEN1 Peptide |
|
MBS3233014-5x01mg |
MyBiosource |
5x0.1mg |
EUR 730 |
FEN1 Rabbit mAb |
|
MBS4753269-01mL |
MyBiosource |
0.1mL |
EUR 450 |
FEN1 Rabbit mAb |
|
MBS4753269-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1540 |
FEN1 Rabbit pAb |
|
MBS8543368-01mL |
MyBiosource |
0.1mL |
EUR 305 |
FEN1 Rabbit pAb |
|
MBS8543368-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
FEN1 Rabbit pAb |
|
MBS8543368-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
FEN1 Rabbit pAb |
|
MBS8543368-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
FEN1 Rabbit pAb |
|
MBS8543368-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
FEN1 Rabbit pAb |
|
MBS8544285-01mL |
MyBiosource |
0.1mL |
EUR 305 |
FEN1 Rabbit pAb |
|
MBS8544285-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
FEN1 Rabbit pAb |
|
MBS8544285-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
FEN1 Rabbit pAb |
|
MBS8544285-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
FEN1 Rabbit pAb |
|
MBS8544285-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
FEN1 Rabbit mAb |
|
MBS9467471-005mL |
MyBiosource |
0.05mL |
EUR 290 |
FEN1 Rabbit mAb |
|
MBS9467471-01mL |
MyBiosource |
0.1mL |
EUR 435 |
FEN1 Rabbit mAb |
|
MBS9467471-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1810 |
-Human flap structure-specific endonuclease 1 (FEN1)) FEN1 (Myc-DDK-tagged)-Human flap structure-specific endonuclease 1 (FEN1) |
|
RC201785 |
Origene Technologies GmbH |
10 µg |
Ask for price |
 FEN1 Antibody |
|
8C10585 |
AAT Bioquest |
50ug |
EUR 368 |
|
Description: FEN1 Antibody |
 FEN1 antibody |
|
70R-31706 |
Fitzgerald |
100 ug |
EUR 294 |
|
|
|
Description: Rabbit polyclonal FEN1 antibody |
FEN1 antibody |
|
70R-49736 |
Fitzgerald |
100 ul |
EUR 242 |
|
|
|
Description: Purified Polyclonal FEN1 antibody |
FEN1 antibody |
|
70R-1605 |
Fitzgerald |
100 ug |
EUR 407 |
|
|
|
Description: Rabbit polyclonal FEN1 antibody raised against the C terminal of FEN1 |
FEN1 antibody |
|
70R-17281 |
Fitzgerald |
50 ul |
EUR 289 |
|
|
|
Description: Rabbit polyclonal FEN1 antibody |
FEN1 Antibody |
|
33763 |
SAB |
100ul |
EUR 319 |
FEN1 Antibody |
|
33763-100ul |
SAB |
100ul |
EUR 302.4 |
FEN1 Antibody |
|
33763-50ul |
SAB |
50ul |
EUR 224.4 |
FEN1 antibody |
|
10R-1738 |
Fitzgerald |
100 ug |
EUR 614.4 |
|
Description: Mouse monoclonal FEN1 antibody |
FEN1 Antibody |
|
32204 |
SAB |
100ul |
EUR 439 |
FEN1 Antibody |
|
32204-100ul |
SAB |
100ul |
EUR 302.4 |
FEN1 Antibody |
|
CSB-PA926648- |
Cusabio |
each |
EUR 402 |
|
|
|
Description: A polyclonal antibody against FEN1. Recognizes FEN1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
FEN1 Antibody |
|
CSB-PA926648-100ul |
Cusabio |
100ul |
EUR 379.2 |
|
|
|
Description: A polyclonal antibody against FEN1. Recognizes FEN1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
FEN1 Antibody |
|
1-CSB-PA002510 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
|
|
Description: A polyclonal antibody against FEN1. Recognizes FEN1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000 |
FEN1 Antibody |
|
1-CSB-PA008585GA01HU |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
|
|
Description: A polyclonal antibody against FEN1. Recognizes FEN1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
FEN1 Antibody |
|
CSB-PA008585KA01HU- |
Cusabio |
each |
EUR 402 |
|
|
|
Description: A polyclonal antibody against FEN1. Recognizes FEN1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
FEN1 Antibody |
|
CSB-PA008585KA01HU-100ul |
Cusabio |
100ul |
EUR 466.8 |
|
|
|
Description: A polyclonal antibody against FEN1. Recognizes FEN1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
 Fen1 Antibody |
|
CSB-PA008585XA01DKY-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila ananassae (Fruit fly) Fen1 protein |
Fen1 Antibody |
|
CSB-PA008585XA01DKY-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila ananassae (Fruit fly) Fen1 protein |
Fen1 Antibody |
|
CSB-PA008585XA01DLK-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila erecta (Fruit fly) Fen1 protein |
Fen1 Antibody |
|
CSB-PA008585XA01DLK-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila erecta (Fruit fly) Fen1 protein |
Fen1 Antibody |
|
CSB-PA008585XA01DMG-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila sechellia (Fruit fly) Fen1 protein |
Fen1 Antibody |
|
CSB-PA008585XA01DMG-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila sechellia (Fruit fly) Fen1 protein |
Fen1 Antibody |
|
CSB-PA008585XA01DMJ-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila simulans (Fruit fly) Fen1 protein |
Fen1 Antibody |
|
CSB-PA008585XA01DMJ-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila simulans (Fruit fly) Fen1 protein |
Fen1 Antibody |
|
CSB-PA008585XA01DMR-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila yakuba (Fruit fly) Fen1 protein |
Fen1 Antibody |
|
CSB-PA008585XA01DMR-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila yakuba (Fruit fly) Fen1 protein |
FEN1 Antibody |
|
CSB-PA008585XA01HU-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Homo sapiens (Human) FEN1 protein |
Single cell transcriptomes reveal expression patterns of chemoreceptor genes in olfactory sensory neurons of the Caribbean spiny lobster, Panulirus argus
Background: Crustaceans categorical a lot of programs of receptor genes of their antennules, which house olfactory sensory neurons (OSNs) and non-olfactory chemosensory neurons. Transcriptomics analysis reveal that candidate chemoreceptor proteins embrace variant Ionotropic Receptors (IRs) along with every co-receptor IRs and tuning IRs, Transient Receptor Potential (TRP) channels, Gustatory Receptors, epithelial sodium channels, and class A G-protein coupled receptors (GPCRs). The Caribbean spiny lobster, Panulirus argus, expresses in its antennules nearly 600 IRs, 17 TRP channels, 1 Gustatory Receptor, 7 epithelial sodium channels, 81 GPCRs, 6 G proteins, and dozens of enzymes in signaling pathways.
Nonetheless, the exact combinatorial expression patterns of these proteins in single sensory neurons normally aren’t acknowledged for any crustacean, limiting our understanding of how their chemosensory strategies encode chemical prime quality.
Outcomes: The aim of this analysis was to utilize transcriptomics to elucidate expression patterns of chemoreceptor genes in OSNs of P. argus. We generated and analyzed transcriptomes from 7 single OSNs, just a few of which have been confirmed to reply a meals odor, along with an additional 7 multicell transcriptomes from preparations containing few (2-4), a lot of (ca. 15), or many (ca. 400) OSNs. We found that each OSN expressed the similar 2 co-receptor IRs (IR25a, IR93a) nevertheless
not the other 2 antennular coIRs (IR8a, IR76b), 9-53 tuning IRs nevertheless only one to some in extreme abundance, the similar 5 TRP channels plus as a lot as 5 further TRPs, 12-17 GPCRs along with the similar 5 expressed in every single cell transcriptome, the similar Three G proteins plus others, many enzymes throughout the signaling pathways, nevertheless no Gustatory Receptors or epithelial sodium channels. One of the best distinction in receptor expression among the many many OSNs was the identification of the tuning IRs.
Conclusions: Our outcomes current an preliminary view of the combinatorial expression patterns of receptor molecules in single OSNs in a single species of decapod crustacean, along with receptors straight involved in olfactory transduction and others probably involved in modulation. Our outcomes moreover counsel variations in receptor expression in OSNs vs. completely different chemosensory neurons.
Camel Genetic Belongings Conservation by Tourism: A Key Sociocultural Technique of Camelback Leisure Driving
- Camels are distinctive components, which can be comprised inside journey journey companies promoting ecotourism actions. Such recreations contribute to sustainable livelihoods for native communities and educational empowerment within the path of nature and its conservation. At present, some native camel breeds’ survival reduces to this animal-based leisure enterprise and its reliability to hold out and promote custom-made firms By conducting an on-site questionnaire to prospects participating in camelback driving excursions, we assessed the motivational elements affecting participation, satisfaction, and loyalty on this tourism part that can have made it socially differentiated.
- The sixfold combination of staff effectivity, custom geography, quite a few and humane shut interaction, camel conduct and effectivity, sociotemporal context, and constructive earlier experience consists of the elemental dimensions that designate purchaser satisfaction and return intention likelihood inside this leisure enterprise.
- Purchaser knowledge is essential for stakeholders to assemble personalised driving experiences and align revenue with environmental sustainability and biodiversity mainstream issues into their frequently operations. In flip, house camel vacationer rides is likely to be managed as a viable path to nature conservation by serving to endangered native breeds to stay away from their helpful devaluation and potential extinction.
Connexin Genes Variants Related to Non-Syndromic Listening to Impairment: A Systematic Evaluate of the International Burden
Mutations in connexins are the commonest causes of listening to impairment (HI) in lots of populations. Our goal was to overview the worldwide burden of pathogenic and certain pathogenic (PLP) variants in connexin genes related to HI. We carried out a scientific overview of the literature primarily based on focused inclusion/exclusion standards of publications from 1997 to 2020. The databases used had been PubMed, Scopus, Africa-Extensive Data, and Net of Science.
The protocol was registered on PROSPERO, the Worldwide Potential Register of Systematic Critiques, with the registration quantity “CRD42020169697”. The info extracted had been analyzed utilizing Microsoft Excel and SPSS model 25 (IBM, Armonk, New York, United States). A complete of 571 impartial research had been retrieved and thought of for knowledge extraction with nearly all of research (47.8% (n = 289)) carried out in Asia.
Focused sequencing was discovered to be the commonest method utilized in investigating connexin gene mutations. We recognized seven connexin genes that had been related to HI, and GJB2 (520/571 publications) was probably the most studied among the many seven.
Excluding PLP in GJB2, GJB6, and GJA1 the opposite connexin gene variants (thus GJB3, GJB4, GJC3, and GJC1 variants) had conflicting affiliation with HI. Biallelic GJB2 PLP variants had been the commonest and widespread variants related to non-syndromic listening to impairment (NSHI) in numerous world populations however absent in most African populations.
The commonest GJB2 alleles discovered to be predominant in particular populations embrace; p.Gly12ValfsTer2 in Europeans, North Africans, Brazilians, and Individuals; p.V37I and p.L79Cfs in Asians; p.W24X in Indians; p.L56Rfs in Individuals; and the founder mutation p.R143W in Africans from Ghana, or with putative Ghanaian ancestry.
The current overview means that solely GJB2 and GJB3 are acknowledged and validated HI genes. The findings name for an in depth investigation of the opposite connexin genes in lots of populations to elucidate their contributions to HI, in an effort to enhance gene-disease pair curations, globally.
 Afatinib free base |
|
MBS5756697-10mg |
MyBiosource |
10mg |
EUR 145 |
Afatinib free base |
|
MBS5756697-200mg |
MyBiosource |
200mg |
EUR 250 |
Afatinib free base |
|
MBS5756697-50mg |
MyBiosource |
50mg |
EUR 195 |
Afatinib free base |
|
MBS5756697-5x200mg |
MyBiosource |
5x200mg |
EUR 965 |
 Afatinib |
|
A170-100MG |
TOKU-E |
100mg |
EUR 63.39 |
|
|
|
Description: 850140-72-6 |
Afatinib |
|
27009 |
BPS Bioscience |
25 mg |
EUR 115 |
|
Description: Afatinib, also known as BIW-2992, is an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinases. Afatinib suppresses EGF-induced EGFR phosphorylation and cellular proliferation in various cell lines, including EGFR-overexpressing and HER2-expressing cell lines A431, NIH-3T3-HER2, NCI-N87 and BT-474. |
Afatinib |
|
HY-10261 |
MedChemExpress |
200mg |
EUR 155.85 |
|
Description: Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer[1][2][3][4]. |
Afatinib |
|
MBS3842612-5x100mg |
MyBiosource |
5x100mg |
EUR 1910 |
-Afatinib) (R)-Afatinib |
|
HY-10261E |
MedChemExpress |
Get quote |
Ask for price |
|
Description: (R)-Afatinib ((R)-BIBW 2992) is the Afatinib isomer. Afatinib (HY-10261) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer[1]. |
 Afatinib-d6 |
|
HY-10261S |
MedChemExpress |
1 mg |
EUR 616.89 |
|
Description: Afatinib-d6 is deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor[1]. |
 Afatinib-d4 |
|
HY-10261S1 |
MedChemExpress |
1mg |
Ask for price |
|
Description: Afatinib-d4 is the deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. |
) Afatinib (oxalate) |
|
HY-10261D |
MedChemExpress |
Get quote |
Ask for price |
|
Description: Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer[1][2][3][4]. |
 Afatinib oxalate |
|
T64075-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Afatinib oxalate |
Afatinib oxalate |
|
T64075-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Afatinib oxalate |
Afatinib oxalate |
|
T64075-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Afatinib oxalate |
Afatinib oxalate |
|
T64075-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Afatinib oxalate |
) Afatinib (BIBW2992) |
|
A8247-10 |
ApexBio |
10 mg |
EUR 68 |
|
|
|
Description: JAK/STAT Signaling|EGFR#Tyrosine Kinase|EGFR#Tyrosine Kinase|HER2 |
Afatinib (BIBW2992) |
|
A8247-5 |
ApexBio |
5 mg |
EUR 40 |
|
|
|
Description: JAK/STAT Signaling|EGFR#Tyrosine Kinase|EGFR#Tyrosine Kinase|HER2 |
Afatinib (BIBW2992) |
|
A8247-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 60 |
|
|
|
Description: JAK/STAT Signaling|EGFR#Tyrosine Kinase|EGFR#Tyrosine Kinase|HER2 |
Afatinib (BIBW2992) |
|
A8247-50 |
ApexBio |
50 mg |
EUR 88 |
|
|
|
Description: JAK/STAT Signaling|EGFR#Tyrosine Kinase|EGFR#Tyrosine Kinase|HER2 |
Afatinib (BIBW2992) |
|
A8247-S |
ApexBio |
Evaluation Sample |
EUR 24 |
|
|
|
Description: JAK/STAT Signaling|EGFR#Tyrosine Kinase|EGFR#Tyrosine Kinase|HER2 |
Afatinib (BIBW2992) |
|
MBS578066-10mg |
MyBiosource |
10mg |
EUR 195 |
Afatinib (BIBW2992) |
|
MBS578066-25mg |
MyBiosource |
25mg |
EUR 260 |
Afatinib (BIBW2992) |
|
MBS578066-2mg |
MyBiosource |
2mg |
EUR 145 |
Afatinib (BIBW2992) |
|
MBS578066-50mg |
MyBiosource |
50mg |
EUR 370 |
Afatinib (BIBW2992) |
|
MBS578066-5mg |
MyBiosource |
5mg |
EUR 155 |
) BIBW2992 (Afatinib) |
|
MBS386306-100mg |
MyBiosource |
100mg |
EUR 285 |
BIBW2992 (Afatinib) |
|
MBS386306-10mg |
MyBiosource |
10mg |
EUR 140 |
BIBW2992 (Afatinib) |
|
MBS386306-1mLinDMSO |
MyBiosource |
1mL(inDMSO) |
EUR 140 |
BIBW2992 (Afatinib) |
|
MBS386306-25mg |
MyBiosource |
25mg |
EUR 160 |
BIBW2992 (Afatinib) |
|
MBS386306-5mg |
MyBiosource |
5mg |
EUR 130 |
 Afatinib dimaleate |
|
A3145-10 |
ApexBio |
10 mg |
EUR 56 |
|
|
|
Description: Tyrosine Kinase|HER2 |
Afatinib dimaleate |
|
A3145-5 |
ApexBio |
5 mg |
EUR 40 |
|
|
|
Description: Tyrosine Kinase|HER2 |
Afatinib dimaleate |
|
A3145-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 48 |
|
|
|
Description: Tyrosine Kinase|HER2 |
Afatinib dimaleate |
|
A3145-50 |
ApexBio |
50 mg |
EUR 88 |
|
|
|
Description: Tyrosine Kinase|HER2 |
) Afatinib (dimaleate) |
|
HY-10261A |
MedChemExpress |
200mg |
EUR 171 |
|
Description: Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer[1][2][3][4]. |
Afatinib dimaleate |
|
MBS3840747-100mg |
MyBiosource |
100mg |
EUR 240 |
Afatinib dimaleate |
|
MBS3840747-25mg |
MyBiosource |
25mg |
EUR 165 |
Afatinib dimaleate |
|
MBS3840747-50mg |
MyBiosource |
50mg |
EUR 200 |
Afatinib dimaleate |
|
MBS3840747-5x100mg |
MyBiosource |
5x100mg |
EUR 1065 |
Afatinib dimaleate |
|
MBS3606168-100mg |
MyBiosource |
100mg |
EUR 275 |
Afatinib dimaleate |
|
MBS3606168-10mg |
MyBiosource |
10mg |
EUR 210 |
Afatinib dimaleate |
|
MBS3606168-200mg |
MyBiosource |
200mg |
EUR 320 |
Afatinib dimaleate |
|
MBS3606168-25mg |
MyBiosource |
25mg |
EUR 225 |
Afatinib dimaleate |
|
MBS3606168-50mg |
MyBiosource |
50mg |
EUR 250 |
 Afatinib Dimaleate |
|
T1773-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Afatinib Dimaleate |
Afatinib Dimaleate |
|
T1773-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: Afatinib Dimaleate |
Afatinib Dimaleate |
|
T1773-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Afatinib Dimaleate |
Afatinib Dimaleate |
|
T1773-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Afatinib Dimaleate |
Afatinib Dimaleate |
|
T1773-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Afatinib Dimaleate |
-Afatinib) (E/Z)-Afatinib |
|
HY-10261B |
MedChemExpress |
100 mg |
EUR 54.11 |
|
Description: (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells[1]. |
) BIBW 2992 (Afatinib) |
|
abx283009-100g |
Abbexa |
100 µg |
Ask for price |
BIBW 2992 (Afatinib) |
|
abx283009-20g |
Abbexa |
20 µg |
EUR 156.25 |
BIBW 2992 (Afatinib) |
|
abx283009-50g |
Abbexa |
50 µg |
EUR 387.5 |
 Afatinib N-Oxide |
|
HY-133110 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: Afatinib N-Oxide is an impurity of Afatinib dimaleate in oxidative degradation. Afatinib dimaleate is an irreversible EGFR family inhibitor[1]. |
Afatinib N-Oxide |
|
T10257-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Afatinib N-Oxide |
Afatinib N-Oxide |
|
T10257-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Afatinib N-Oxide |
Afatinib N-Oxide |
|
T10257-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Afatinib N-Oxide |
Afatinib N-Oxide |
|
T10257-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Afatinib N-Oxide |
 Afatinib impurity 11 |
|
HY-133780 |
MedChemExpress |
1 mg |
EUR 1439.42 |
|
Description: Afatinib impurity 11 is an impurity of Afatinib. Afatinib is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively[1]. |
Afatinib impurity 11 |
|
MBS5796779-1mg |
MyBiosource |
1(mg |
EUR 185 |
Afatinib impurity 11 |
|
MBS5796779-5mg |
MyBiosource |
5(mg |
EUR 345 |
Afatinib impurity 11 |
|
MBS5796779-5x5mg |
MyBiosource |
5x5(mg |
EUR 1410 |
Afatinib impurity 11 |
|
T35430-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Afatinib impurity 11 |
Afatinib impurity 11 |
|
T35430-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: Afatinib impurity 11 |
Afatinib impurity 11 |
|
T35430-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Afatinib impurity 11 |
Afatinib impurity 11 |
|
T35430-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Afatinib impurity 11 |
Afatinib impurity 11 |
|
T35430-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Afatinib impurity 11 |
) Afatinib-d6 (dimaleate) |
|
HY-10261AS |
MedChemExpress |
1mg |
Ask for price |
|
Description: Afatinib-d6 (dimaleate) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively[1][2]. |
 Dimaleate) Afatinib (BIBW2992) Dimaleate |
|
MBS577991-100mg |
MyBiosource |
100mg |
EUR 215 |
Afatinib (BIBW2992) Dimaleate |
|
MBS577991-10mg |
MyBiosource |
10mg |
EUR 145 |
Afatinib (BIBW2992) Dimaleate |
|
MBS577991-200mg |
MyBiosource |
200mg |
EUR 255 |
Afatinib (BIBW2992) Dimaleate |
|
MBS577991-25mg |
MyBiosource |
25mg |
EUR 165 |
Afatinib (BIBW2992) Dimaleate |
|
MBS577991-5mg |
MyBiosource |
5mg |
EUR 145 |
 (Afatinib/BIBW-2992) EGFR/HER2 kinase inhibitor (>99%, M.wt 485.94) (Afatinib/BIBW-2992 |
|
SM-101000-5 |
Alpha Diagnostics |
5 mg |
EUR 196.8 |
EGFR/HER2 kinase inhibitor (>99%, M.wt 485.94) (Afatinib/BIBW-2992 |
|
SM-101000-50 |
Alpha Diagnostics |
50 mg |
EUR 781.2 |
butyl Afatinib) Desfluoro-N-des(4-dimethylamino-2-en-1-oxo)butyl Afatinib |
|
D289815 |
Toronto Research Chemicals |
2.5g |
EUR 1800 |
|
|
|
Description: 2413212-09-4 |
butyl (Contained ~8.5% Ethanol)) Afatinib-des(4-dimethylamino-2-en-1-oxo)butyl (Contained ~8.5% Ethanol) |
|
A355320 |
Toronto Research Chemicals |
100mg |
EUR 276 |
|
|
|
Description: 314771-76-1 |
butylamino 6-(5-Amino-pyrrolidin-2-on-1-yl) Afatinib) Des-(4-dimethylamino-2-en-1-oxo)butylamino 6-(5-Amino-pyrrolidin-2-on-1-yl) Afatinib |
|
D291248 |
Toronto Research Chemicals |
10mg |
EUR 759 |
|
|
butylamino 6-(5-Hydroxy-pyrrolidin-2-on-1-yl) Afatinib) Des-(4-dimethylamino-2-en-1-oxo)butylamino 6-(5-Hydroxy-pyrrolidin-2-on-1-yl) Afatinib |
|
D291245 |
Toronto Research Chemicals |
10mg |
EUR 874 |
|
|
)) I-37 free base (2359690-13-2(free base)) |
|
MBS5759495-10mg |
MyBiosource |
10mg |
EUR 470 |
I-37 free base (2359690-13-2(free base)) |
|
MBS5759495-1mg |
MyBiosource |
1mg |
EUR 210 |
I-37 free base (2359690-13-2(free base)) |
|
MBS5759495-25mg |
MyBiosource |
25mg |
EUR 780 |
I-37 free base (2359690-13-2(free base)) |
|
MBS5759495-50mg |
MyBiosource |
50mg |
EUR 1130 |
I-37 free base (2359690-13-2(free base)) |
|
MBS5759495-5mg |
MyBiosource |
5mg |
EUR 335 |
)) I-37 free base( 2359690-13-2(free base)) |
|
T8721L-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: I-37 free base( 2359690-13-2(free base)) |
I-37 free base( 2359690-13-2(free base)) |
|
T8721L-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: I-37 free base( 2359690-13-2(free base)) |
I-37 free base( 2359690-13-2(free base)) |
|
T8721L-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: I-37 free base( 2359690-13-2(free base)) |
I-37 free base( 2359690-13-2(free base)) |
|
T8721L-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: I-37 free base( 2359690-13-2(free base)) |
I-37 free base( 2359690-13-2(free base)) |
|
T8721L-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: I-37 free base( 2359690-13-2(free base)) |
) THZ1 (Free base) |
|
9664-25 |
Biovision |
each |
EUR 1227.6 |
THZ1 (Free base) |
|
9664-5 |
Biovision |
each |
EUR 352.8 |
) R406 (free base) |
|
A5880-100 |
ApexBio |
100 mg |
EUR 800 |
|
|
|
Description: Tyrosine Kinase|Spleen Tyrosine Kinase (Syk) |
R406 (free base) |
|
A5880-25 |
ApexBio |
25 mg |
EUR 320 |
|
|
|
Description: Tyrosine Kinase|Spleen Tyrosine Kinase (Syk) |
R406 (free base) |
|
A5880-5 |
ApexBio |
5 mg |
EUR 80 |
|
|
|
Description: Tyrosine Kinase|Spleen Tyrosine Kinase (Syk) |
R406 (free base) |
|
A5880-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 148 |
|
|
|
Description: Tyrosine Kinase|Spleen Tyrosine Kinase (Syk) |
R406 (free base) |
|
A5880-S |
ApexBio |
Evaluation Sample |
EUR 24 |
|
|
|
Description: Tyrosine Kinase|Spleen Tyrosine Kinase (Syk) |
) FIPI (free base) |
|
B2372-25 |
Biovision |
each |
EUR 757.2 |
FIPI (free base) |
|
B2372-5 |
Biovision |
each |
EUR 235.2 |
) R406(free base) |
|
MBS131267-100mg |
MyBiosource |
100mg |
EUR 1065 |
R406(free base) |
|
MBS131267-500mg |
MyBiosource |
500mg |
EUR 2775 |
) SIS3 (free base) |
|
HY-100444 |
MedChemExpress |
10 mg |
EUR 1244.61 |
|
Description: SIS3 free base is a potent and selective inhibitor of Smad3 phosphorylation. SIS3 free base inhibits the myofibroblast differentiation of fibroblasts by TGF-β1. SIS3 free base does not affect the phosphorylation of Smad2[1]. |
R406 (free base) |
|
HY-11108 |
MedChemExpress |
10mM/1mL |
EUR 465.38 |
|
Description: R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 free base reduces immune complex-mediated inflammation[1]. R406 free base also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM)[2]. |
R406(free base) |
|
E1KS1533 |
EnoGene |
2mg |
EUR 362.4 |
 SIS3 free base |
|
MBS5767611-5x5mg |
MyBiosource |
5x5mg |
EUR 3970 |
 R406 free base |
|
MBS3606124-10mg |
MyBiosource |
10mg |
EUR 305 |
R406 free base |
|
MBS3606124-25mg |
MyBiosource |
25mg |
EUR 405 |
R406 free base |
|
MBS3606124-50mg |
MyBiosource |
50mg |
EUR 620 |
 R788 free base |
|
MBS3606474-10mg |
MyBiosource |
10mg |
EUR 315 |
R788 free base |
|
MBS3606474-25mg |
MyBiosource |
25mg |
EUR 430 |
R788 free base |
|
MBS3606474-5x25mg |
MyBiosource |
5x25mg |
EUR 1620 |
R406 (free base) |
|
MBS8506526-2mg |
MyBiosource |
2mg |
EUR 440 |
R406 (free base) |
|
MBS8506526-5x2mg |
MyBiosource |
5x2mg |
EUR 1835 |
Tags:
reagents coa,
reagents cost,
reagents dbd,
reagents define,
reagents defined,
reagents definition,
reagents eso,
reagents in lab,
reagents in organic chemistry,
reagents llc,
reagents nc,
reagents orgrimmar,
reagents orgrimmar classic wow,
reagents pdf,
reagents qc,
reagents s.a,
reagents sds,
reagents specialty chemicals,
reagents specialty chemicals and solutions,
reagents usp,
ria kitsch,
vector virus definition,
vector virus example,
vector virus introduction,
vector virus relationship,
victor virus,
victor virus cartoonmania
